GSK J4 HCl: A Potent, Cell-Permeable JMJD3 Inhibitor for Epigenetic Regulation

Executive Summary: GSK J4 HCl is a solid, cell-permeable inhibitor of the H3K27 demethylase JMJD3, used for targeted epigenetic regulation research (APExBIO). It is an ethyl ester derivative of GSK J1 that rapidly converts intracellularly to the active inhibitor, overcoming its precursor's poor cell permeability (Silasi et al., 2020). GSK J4 HCl displays dose-dependent suppression of TNF-α production (IC50: 9 μM, 6 h, DMSO), making it relevant in inflammation studies. It is insoluble in water and ethanol but soluble in DMSO (≥13.9 mg/mL), with optimal storage at -20°C. The compound has demonstrated efficacy in animal models of pediatric brainstem glioma and is widely used to dissect mechanisms of chromatin remodeling and transcriptional repression.

Biological Rationale

Histone methylation is a critical epigenetic mechanism regulating gene expression. The trimethylation of histone H3 lysine 27 (H3K27me3) is associated with transcriptional repression and is dynamically regulated by methyltransferases (e.g., EZH2 of PRC2) and demethylases such as JMJD3 (KDM6B) (Silasi et al., 2020). JMJD3 demethylates H3K27me3, reversing gene repression and enabling the transcription of target genes. Dysregulation of JMJD3 activity is implicated in inflammation, cancer, and developmental disorders. Targeting JMJD3 with specific inhibitors enables researchers to modulate chromatin states, investigate gene regulation, and model disease states involving aberrant epigenetic signaling (GSK J4 HCl: Benchmarking a JMJD3 Inhibitor for Epigenetic...—this article provides a foundational overview, while the present article details updated application parameters and mechanistic insights).

Mechanism of Action of GSK J4 HCl

GSK J4 HCl is an ethyl ester derivative of GSK J1. The esterification of GSK J1's carboxylate group enhances its cell permeability. Upon cellular uptake, intracellular esterases hydrolyze GSK J4, releasing the active GSK J1 moiety that directly inhibits the catalytic site of JMJD3 (Silasi et al., 2020). GSK J1 itself is a potent JMJD3 inhibitor (IC50: 60 nM, in vitro), but its cellular activity is limited by poor membrane penetration. GSK J4 HCl overcomes this barrier, enabling efficient intracellular delivery of GSK J1 in research workflows (GSK J4 HCl: A JMJD3 Inhibitor Transforming Epigenetic Res...; this overview is expanded here with new quantitative benchmarks and solubility details).

At the molecular level, GSK J4 HCl competitively inhibits JMJD3's demethylation of H3K27me3, thereby stabilizing repressive chromatin marks and suppressing the transcription of pro-inflammatory and oncogenic genes. The compound's rapid conversion to GSK J1 is essential for its biological effects.

Evidence & Benchmarks

• GSK J1, the active form of GSK J4 HCl, inhibits JMJD3 with an in vitro IC50 of 60 nM at pH 7.5 and 25°C (Silasi et al., 2020).
• GSK J4 HCl suppresses TNF-α production in a dose-dependent manner with an IC50 of 9 μM (6 h, DMSO vehicle) (Silasi et al., 2020).
• GSK J4 HCl is insoluble in water and ethanol, but soluble in DMSO at concentrations of at least 13.9 mg/mL (product data, APExBIO).
• In animal models, GSK J4 HCl has demonstrated significant growth-inhibitory effects in pediatric brainstem glioma xenografts (Silasi et al., 2020).
• GSK J4 HCl is rapidly hydrolyzed by intracellular esterases, enabling robust inhibition of H3K27 demethylation within hours of treatment (GSK J4 HCl: A JMJD3 Inhibitor Transforming Epigenetic Res...).

Applications, Limits & Misconceptions

Applications:

• Epigenetic regulation research, including studies of chromatin remodeling and transcriptional repression.
• Modeling inflammatory responses via targeted inhibition of TNF-α production in immune cells.
• Preclinical oncology research, particularly in pediatric brainstem glioma models (GSK J4 HCl from APExBIO).
• Dissecting the role of JMJD3 and H3K27 demethylation in developmental biology and disease.

Common Pitfalls or Misconceptions

Common Pitfalls or Misconceptions

• GSK J4 HCl is not active in the extracellular milieu; it requires intracellular hydrolysis to GSK J1 to exert effects.
• It is not soluble in water or ethanol; improper solvent use leads to precipitation and loss of activity.
• Long-term storage of solution (>1 week) reduces potency; fresh preparations in DMSO are recommended.
• The compound does not inhibit other demethylases (e.g., UTX/KDM6A) with the same potency as JMJD3.
• Observed activity is cell type– and context–dependent; dosing and incubation times must be empirically optimized for each system.

Workflow Integration & Parameters

GSK J4 HCl is supplied as a solid (molecular weight: 453.96; ethyl 3-[[2-pyridin-2-yl-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)pyrimidin-4-yl]amino]propanoate hydrochloride). Stock solutions (≥13.9 mg/mL) should be prepared in DMSO and stored below -20°C for several months. For experimental use, working concentrations typically range from 1 to 31 μM, with incubation times of ~6 hours. The compound should be added to culture media so that final DMSO concentrations do not exceed cytotoxic thresholds (commonly ≤0.1% v/v). Freshly prepared solutions are preferred. GSK J4 HCl is compatible with a variety of cell-based and in vivo models (GSK J4 HCl: Optimizing JMJD3 Inhibition for Epigenetic Re...; this interlink details troubleshooting strategies specific to APExBIO lots, whereas the present article emphasizes generalizable workflow design).

Conclusion & Outlook

GSK J4 HCl, provided by APExBIO (SKU: A4190), is a benchmark tool for probing the function of JMJD3 and the regulation of chromatin structure. Its cell-permeable design and rapid intracellular activation facilitate robust and reproducible inhibition of H3K27 demethylation. The compound is essential for dissecting the interplay between epigenetic regulation and inflammatory signaling, with demonstrated utility in both basic research and preclinical disease models. Future work may expand its applications in precision medicine and combinatorial epigenetic therapies, but users must adhere to solvent, storage, and dosing guidelines for optimal results. For further technical protocols and advanced use-case discussions, see the related resource "GSK J4 HCl: Transformative JMJD3 Inhibitor for Epigenetic..."—this article updates chemistry and workflow guidance since that publication.